Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

Journal:
Journal of the American Academy of Dermatology
Published:
DOI:
10.1016/j.jaad.2025.11.031
Affiliations:
25
Authors:
17
Go to article
Institutions Authors Share
European Hidradenitis Suppurativa Foundation e.V. (EHSF), Germany
2.083333
 0.12
UCB Inc., United States of America (USA)
2.000000
 0.12
Nagoya City University, Japan
1.000000
 0.06
UCB - France, France
1.000000
 0.06
Beth Israel Deaconess Medical Center (BIDMC), United States of America (USA)
1.000000
 0.06
UCB Pharma Limited, United Kingdom (UK)
1.000000
 0.06
Northwell Health, United States of America (USA)
1.000000
 0.06
University of California, San Francisco (UCSF), United States of America (USA)
1.000000
 0.06
UCB - Poland, Poland
1.000000
 0.06
UCB, Belgium
1.000000
 0.06
Charité - University Medicine Berlin, Germany
1.000000
 0.06
St. Vincent's University Hospital, Ireland
0.500000
 0.03
The University of North Carolina at Chapel Hill (UNC), United States of America (USA)
0.500000
 0.03
St. Josef-Hospital, RUB, Germany
0.500000
 0.03
Ruhr University Bochum (RUB), Germany
0.500000
 0.03
Cardiff University, United Kingdom (UK)
0.500000
 0.03
Dessau Medical Center, Germany
0.333333
 0.02
Brandenburg Medical School - Theodor Fontane (MHB), Germany
0.333333
 0.02
Herlev University Hospital, Denmark
0.250000
 0.01
Gentofte University Hospital, Denmark
0.250000
 0.01
University of Copenhagen (UCPH), Denmark
0.250000
 0.01
Interested in Clinical Sciences?